JPWO2020214734A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020214734A5 JPWO2020214734A5 JP2021561601A JP2021561601A JPWO2020214734A5 JP WO2020214734 A5 JPWO2020214734 A5 JP WO2020214734A5 JP 2021561601 A JP2021561601 A JP 2021561601A JP 2021561601 A JP2021561601 A JP 2021561601A JP WO2020214734 A5 JPWO2020214734 A5 JP WO2020214734A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 33
- 229910052801 chlorine Inorganic materials 0.000 claims description 18
- 229910052731 fluorine Inorganic materials 0.000 claims description 18
- 229910052794 bromium Inorganic materials 0.000 claims description 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- 239000012453 solvate Substances 0.000 claims 16
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical group 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 5
- 125000006747 (C2-C10) heterocycloalkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 claims 1
- 206010068873 Adenosquamous cell carcinoma Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 201000004404 Neurofibroma Diseases 0.000 claims 1
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000002357 endometrial effect Effects 0.000 claims 1
- 208000028653 esophageal adenocarcinoma Diseases 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 201000006585 gastric adenocarcinoma Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000003494 hepatocyte Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 claims 1
- 206010027191 meningioma Diseases 0.000 claims 1
- 208000007538 neurilemmoma Diseases 0.000 claims 1
- 208000029974 neurofibrosarcoma Diseases 0.000 claims 1
- 201000003733 ovarian melanoma Diseases 0.000 claims 1
- 208000012988 ovarian serous adenocarcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 206010039667 schwannoma Diseases 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 21
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 6
- 125000000131 cyclopropyloxy group Chemical group C1(CC1)O* 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- -1 cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, oxetanyloxy, tetrahydrofuranyloxy, tetrahydropyranyloxy, azetidinyl Chemical group 0.000 description 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 3
- 125000003831 tetrazolyl group Chemical group 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962834671P | 2019-04-16 | 2019-04-16 | |
| US62/834,671 | 2019-04-16 | ||
| PCT/US2020/028363 WO2020214734A1 (en) | 2019-04-16 | 2020-04-15 | Bicyclic compounds |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022529642A JP2022529642A (ja) | 2022-06-23 |
| JP2022529642A5 JP2022529642A5 (https=) | 2023-04-19 |
| JPWO2020214734A5 true JPWO2020214734A5 (https=) | 2023-04-19 |
| JP7653362B2 JP7653362B2 (ja) | 2025-03-28 |
Family
ID=72838396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021561601A Active JP7653362B2 (ja) | 2019-04-16 | 2020-04-15 | 二環式化合物 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11420935B2 (https=) |
| EP (1) | EP3956033B1 (https=) |
| JP (1) | JP7653362B2 (https=) |
| KR (1) | KR102909464B1 (https=) |
| CN (1) | CN114072207B (https=) |
| AU (1) | AU2020257207A1 (https=) |
| BR (1) | BR112021020629A2 (https=) |
| CA (1) | CA3137025A1 (https=) |
| DK (1) | DK3956033T3 (https=) |
| ES (1) | ES3014444T3 (https=) |
| FI (1) | FI3956033T3 (https=) |
| HU (1) | HUE070525T2 (https=) |
| IL (1) | IL287222B2 (https=) |
| MX (1) | MX2021012638A (https=) |
| PL (1) | PL3956033T3 (https=) |
| SG (1) | SG11202111404XA (https=) |
| TW (1) | TWI849107B (https=) |
| WO (1) | WO2020214734A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3118752A1 (en) | 2018-11-09 | 2020-05-14 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| HUE070525T2 (hu) | 2019-04-16 | 2025-06-28 | Vivace Therapeutics Inc | Biciklusos vegyületek |
| CN115279368B (zh) * | 2019-11-20 | 2024-05-24 | 维瓦斯治疗公司 | 杂芳基化合物 |
| US11787775B2 (en) | 2020-07-24 | 2023-10-17 | Genentech, Inc. | Therapeutic compounds and methods of use |
| WO2022120355A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| MX2023008420A (es) | 2021-01-25 | 2023-09-29 | Ikena Oncology Inc | Combinación de un inhibidor de dominios asociados mejorados transcripcionales (tead) de 3-(imidazol-4-il)-4-(amino)- bencenosulfonamida con un inhibidor del factor de crecimiento epidérmico (egfr) y/o un inhibidor de proteína cinasa-cinasas activadas por mitógen (mek) para usarse en el tratamiento de cáncer de pulmón. |
| EP4284380A4 (en) * | 2021-01-26 | 2024-12-18 | The United States Government as represented by the Department of Veterans Affairs | COMPOSITIONS AND METHODS FOR INHIBITING YAP |
| JP2024514879A (ja) | 2021-04-16 | 2024-04-03 | イケナ オンコロジー， インコーポレイテッド | Ｍｅｋ阻害剤及びその使用 |
| JP2024517473A (ja) * | 2021-05-11 | 2024-04-22 | オプナ バイオ ソシエテ アノニム | Ｙａｐ／ｔｅａｄの調節のための化合物及び方法ならびにそれらの適用 |
| CN117337193A (zh) * | 2021-05-19 | 2024-01-02 | 基因泰克公司 | 组合疗法 |
| WO2022272036A1 (en) * | 2021-06-25 | 2022-12-29 | Cedilla Therapeutics, Inc. | Tead inhibitors and uses thereof |
| WO2023057371A1 (en) | 2021-10-04 | 2023-04-13 | Basilea Pharmaceutica International Ag, Allschwil | 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer |
| WO2023060227A1 (en) | 2021-10-07 | 2023-04-13 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| JP2025503945A (ja) * | 2022-01-28 | 2025-02-06 | オプナ バイオ ソシエテ アノニム | Ｙａｐ／ｔｅａｄ調節およびそれらの適応症のための化合物および方法 |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| AU2023237749A1 (en) * | 2022-03-22 | 2024-11-07 | Sporos Biodiscovery, Inc. | Tead inhibitors and methods of use |
| IL316768A (en) | 2022-05-25 | 2025-01-01 | Ikena Oncology Inc | MEK inhibitors and their uses |
| WO2024013736A1 (en) * | 2022-07-12 | 2024-01-18 | Adama Makhteshim Ltd. | Process for preparing substituted benzamides |
| AU2023349151A1 (en) | 2022-09-29 | 2025-04-03 | Insilico Medicine Ip Limited | Tead inhibitors and methods of uses thereof |
| WO2024092116A1 (en) | 2022-10-26 | 2024-05-02 | Ikena Oncology, Inc. | Combination of tead inhibitors and egfr inhibitors and uses thereof |
| EP4596561A1 (en) * | 2022-10-27 | 2025-08-06 | Suzhou Genhouse Bio Co., Ltd. | Phosphorus-containing compound, pharmaceutical composition and use thereof |
| TW202421158A (zh) | 2022-11-18 | 2024-06-01 | 瑞士商諾華公司 | 藥物組合及其用途 |
| WO2024173761A1 (en) | 2023-02-17 | 2024-08-22 | Ikena Oncology, Inc. | Combinations comprising mek inhibitors for use in the treatment of cancer |
| WO2024176130A1 (en) | 2023-02-23 | 2024-08-29 | Novartis Ag | Tead- and her2-inhibitor combinations for treating cancer |
| WO2024176131A1 (en) | 2023-02-23 | 2024-08-29 | Novartis Ag | Tead- and kras g12d-inhibitor combinations for treating cancer |
| EP4688730A1 (en) * | 2023-03-27 | 2026-02-11 | Vivace Therapeutics, Inc. | Synthesis of a hippo-yap pathway modulator and a polymorph thereof |
| EP4694875A1 (en) * | 2023-04-14 | 2026-02-18 | Vivace Therapeutics, Inc. | Pharmaceutical formulations and dosing schedules of a hippo-yap pathway modulator |
| TW202448857A (zh) * | 2023-05-12 | 2024-12-16 | 大陸商正大天晴藥業集團股份有限公司 | 含有芳香二並環的化合物 |
| WO2024240840A1 (en) * | 2023-05-24 | 2024-11-28 | Beactica Therapeutics Ab | Aromatic amides and conjugates thereof as binders to tead |
| WO2025034563A1 (en) * | 2023-08-04 | 2025-02-13 | Vivace Therapeutics, Inc. | Compounds and methods for treating cancer |
| WO2025101655A1 (en) * | 2023-11-08 | 2025-05-15 | Vivace Therapeutics, Inc. | Compounds for modulating yap-tead/hippo pathway |
| WO2025122956A1 (en) * | 2023-12-08 | 2025-06-12 | Vivace Therapeutics, Inc. | Combination therapy |
| WO2025215527A2 (en) | 2024-04-10 | 2025-10-16 | Novartis Ag | Pharmaceutical combinations and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL135495A (en) | 1995-09-28 | 2002-12-01 | Hoechst Ag | Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid |
| JP2001511813A (ja) | 1997-02-18 | 2001-08-14 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | Ｃｒｆレセプターアンタゴニストおよびそれらに関連する方法 |
| DE69831506T2 (de) | 1997-12-22 | 2006-06-29 | Pharmacia & Upjohn Co. Llc, Kalamazoo | 4-hydroxychinolin-3-carboxamide und hydrazide als antivirale wirkstoffe |
| IT1303123B1 (it) | 1998-10-13 | 2000-10-30 | Rotta Research Lab | Derivati basici di benz(e)isoindol-1-oni e pirrolo(3,4-c)chinolin-1-oni ad attivita' 5ht3 antagonista, loro preparazione ed |
| WO2000075145A1 (en) | 1999-06-03 | 2000-12-14 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| AUPQ841300A0 (en) | 2000-06-27 | 2000-07-20 | Fujisawa Pharmaceutical Co., Ltd. | New aminoalcohol derivatives |
| EP1337524A1 (en) | 2000-11-02 | 2003-08-27 | AstraZeneca AB | Substituted quinolines as antitumor agents |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| WO2005014533A2 (en) | 2003-08-08 | 2005-02-17 | Transtech Pharma, Inc. | Aryl and heteroaryl compounds, compositions, and methods of use |
| WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
| WO2006080477A1 (en) * | 2005-01-25 | 2006-08-03 | Tanabe Seiyaku Co., Ltd. | Norvaline derivative and method for preparation thereof |
| EP2476669A1 (en) | 2006-01-27 | 2012-07-18 | Fibrogen, Inc. | Cyanoisoquinoline compounds and methods of use thereof |
| US20070259960A1 (en) | 2006-02-16 | 2007-11-08 | Fibrogen, Inc. | Compounds and methods for treatment of stroke |
| UY30183A1 (es) | 2006-03-02 | 2007-10-31 | Astrazeneca Ab | Derivados de quinolina |
| JP2010501533A (ja) | 2006-08-21 | 2010-01-21 | アージェンタ ディスカバリー リミテッド | Ｍ３レセプター調節物質として有用な窒素含有複素環化合物 |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| MX2009012117A (es) | 2007-05-09 | 2009-11-23 | Pfizer | Composiciones y derivados heterociclicos sustituidos y su uso farmaceutico como antibacterianos. |
| ES2563477T3 (es) | 2007-08-03 | 2016-03-15 | Biotron Limited | Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina |
| BRPI0819453A2 (pt) | 2007-11-28 | 2014-10-07 | Dana Farber Cancer Inst Inc | Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit |
| WO2009075826A1 (en) | 2007-12-07 | 2009-06-18 | Fibrogen, Inc. | Methods for increasing white blood cells |
| KR20120006016A (ko) | 2009-04-06 | 2012-01-17 | 다이이찌 산쿄 가부시키가이샤 | 치환 페닐기를 갖는 고리형 화합물 |
| US8455476B2 (en) | 2009-04-22 | 2013-06-04 | Janssen Pharmaceutica, Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| KR20130124291A (ko) | 2010-07-02 | 2013-11-13 | 길리애드 사이언시즈, 인코포레이티드 | Ｈｉｖ 항바이러스 화합물로서의 2-퀴놀리닐-아세트산 유도체 |
| JP2013540160A (ja) | 2010-10-22 | 2013-10-31 | ヤンセン ファーマシューティカ エヌ．ベー． | モノアシルグリセロールリパーゼ阻害剤としてのアミノ−ピロリジン−アゼチジンジアミド |
| CA2743391A1 (en) | 2011-05-27 | 2012-11-27 | Queen's University At Kingston | Compounds and methods for catalytic directed ortho substitution of aromatic amides and esters |
| CN104010504B (zh) | 2011-11-03 | 2016-04-06 | 默沙东公司 | 作为mGluR2负变构调节剂的喹啉甲酰胺和喹啉甲腈的衍生物、组合物、及其用途 |
| EP2788332A1 (en) | 2011-12-07 | 2014-10-15 | Amgen, Inc. | Bicyclic aryl and heteroaryl sodium channel inhibitors |
| EP2858635A1 (en) | 2012-06-11 | 2015-04-15 | The Regents of The University of California | Inhibitors of hippo-yap signaling pathway |
| EP2872487B1 (en) | 2012-07-16 | 2017-04-26 | Fibrogen, Inc. | Process for making isoquinoline compounds |
| RU2673549C2 (ru) | 2013-05-03 | 2018-11-28 | Ф. Хоффманн-Ля Рош Аг | Производные изохинолина, стимулирующие нейрогенез |
| US20140336182A1 (en) | 2013-05-13 | 2014-11-13 | Amgen Inc. | Aurora Kinase Modulators and Method of Use |
| WO2014201173A1 (en) | 2013-06-12 | 2014-12-18 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| EP3102569A1 (en) * | 2014-02-06 | 2016-12-14 | AbbVie Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
| US9938292B2 (en) | 2014-03-24 | 2018-04-10 | Guangdong Zhongsheng Pharmaceutical Co., Ltd | Quinoline derivatives as SMO inhibitors |
| EP3247705B1 (en) | 2015-01-20 | 2019-11-20 | Millennium Pharmaceuticals, Inc. | Quinazoline and quinoline compounds and uses thereof as nampt inhibitors |
| WO2016153948A1 (en) | 2015-03-20 | 2016-09-29 | Deuterx, Llc | Combination therapy using enantiopure, oxy-substituted, deuterium-enriched 5-(benzyl)-5-deutero-thiazolidine-2, 4-diones for treatment of medical disorders |
| WO2017058716A1 (en) | 2015-09-28 | 2017-04-06 | Vivace Therapeutics, Inc. | Tricyclic compounds |
| EP3156404A1 (en) | 2015-10-15 | 2017-04-19 | Inventiva | New compounds inhibitors of the yap/taz-tead interaction and their use in the treatment of malignant mesothelioma |
| US11008340B2 (en) | 2015-11-20 | 2021-05-18 | Vitae Pharmaceuticals, Llc | Modulators of ROR-gamma |
| AU2017241837B2 (en) * | 2016-04-01 | 2021-07-22 | Signal Pharmaceuticals, Llc | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith |
| CN107698562A (zh) | 2016-08-09 | 2018-02-16 | 殷建明 | 一种喹啉衍生物及其用途 |
| WO2018204532A1 (en) * | 2017-05-03 | 2018-11-08 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| EP3672947A4 (en) | 2017-08-21 | 2020-12-16 | Drexel University | RENEWABLE FURAN AMINE CURING AGENTS FOR THERMOSETTING EPOXIDIC PLASTIC |
| UA128476C2 (uk) * | 2018-01-26 | 2024-07-24 | Екселіксіс, Інк. | Сполуки для лікування кіназозалежних розладів |
| JP2021512167A (ja) | 2018-01-30 | 2021-05-13 | フォグホーン セラピューティクス インコーポレイテッドＦｏｇｈｏｒｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | 障害を治療するための方法及び化合物 |
| CA3118752A1 (en) | 2018-11-09 | 2020-05-14 | Vivace Therapeutics, Inc. | Bicyclic compounds |
| HUE070525T2 (hu) | 2019-04-16 | 2025-06-28 | Vivace Therapeutics Inc | Biciklusos vegyületek |
| US20240025913A1 (en) | 2020-10-21 | 2024-01-25 | Vivace Therapeutics, Inc. | Tertiary carboxamide compounds |
-
2020
- 2020-04-15 HU HUE20791635A patent/HUE070525T2/hu unknown
- 2020-04-15 DK DK20791635.4T patent/DK3956033T3/da active
- 2020-04-15 CN CN202080044416.7A patent/CN114072207B/zh active Active
- 2020-04-15 WO PCT/US2020/028363 patent/WO2020214734A1/en not_active Ceased
- 2020-04-15 US US16/849,728 patent/US11420935B2/en active Active
- 2020-04-15 IL IL287222A patent/IL287222B2/en unknown
- 2020-04-15 MX MX2021012638A patent/MX2021012638A/es unknown
- 2020-04-15 SG SG11202111404XA patent/SG11202111404XA/en unknown
- 2020-04-15 BR BR112021020629A patent/BR112021020629A2/pt unknown
- 2020-04-15 ES ES20791635T patent/ES3014444T3/es active Active
- 2020-04-15 CA CA3137025A patent/CA3137025A1/en active Pending
- 2020-04-15 KR KR1020217036838A patent/KR102909464B1/ko active Active
- 2020-04-15 AU AU2020257207A patent/AU2020257207A1/en active Pending
- 2020-04-15 JP JP2021561601A patent/JP7653362B2/ja active Active
- 2020-04-15 PL PL20791635.4T patent/PL3956033T3/pl unknown
- 2020-04-15 FI FIEP20791635.4T patent/FI3956033T3/fi active
- 2020-04-15 EP EP20791635.4A patent/EP3956033B1/en active Active
- 2020-04-15 TW TW109112690A patent/TWI849107B/zh active
-
2022
- 2022-05-24 US US17/752,649 patent/US12103902B2/en active Active